Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin

Inclusion Criteria: * Diagnosis of metastatic colon/rectal adenocarcinoma, with measurable by RECIST v. 1.1 * Disease progression to at least two lines of chemotherapy with chemotherapy regimens that contain fluoropyrimidine, irinotecan and oxaliplatin * Patients with RAS research in tumor sample with result wild animals must have previously received anti-EFGR therapy. * ECOG (Eastern Cooperative Oncology Group) 0 or 1 * Availability of tumor material for molecular analysis * Hb \> 8, neutrophils \> 1,500 and PLQ \> 100,000 * Adequate kidney and liver function Exclusion Criteria: * Active neoplasm with other primary site, except in situ tumors * Contraindication to treatment with fluoropyrimidine, oxaliplatin and irinotecan, including previous unmanageable G3 or greater toxicities, in previous exhibitions. * Presence of comorbidities that, according to the investigator's assessment, may compromise participant safety * Prior exposure to the FOLFIRINOX regimen * Pregnant or lactating women * Total bilirubin above 1.5mg/dL * Hepatic transaminases greater than 3 times the upper limit of normality